BIOMAT Database Logo BIOMAT Database Logo

Amiodarone therapy does not compromise subsequent heart transplantation. 1992

C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California, Los Angeles Medical Center.

OBJECTIVE The objective of this study was to determine the frequency of pulmonary complications, feasibility of early hospital discharge and requirements for postoperative inotropic and chronotropic support in patients receiving amiodarone therapy before heart transplantation. BACKGROUND Although many patients waiting for heart transplantation will die of arrhythmias before a donor heart is found, the use of amiodarone has been limited by concern about increased complications in the perioperative period. METHODS The 29 patients receiving amiodarone at the time of heart transplantation at University of California, Los Angeles Medical Center between October 1986 and September 1990 were compared with 29 control recipients to evaluate postoperative morbidity. Patients were receiving amiodarone for recurrent ventricular tachyarrhythmias (n = 11), atrial fibrillation (n = 2) or complex ventricular ectopic activity (n = 16). The average daily dose was 360 +/- 230 mg/day for an average of 11 +/- 22 months before transplantation. Amiodarone and control groups had a similar ejection fraction (0.18 +/- 0.07 vs. 0.20 +/- 0.08), frequency of coronary disease, age and gender. There were three more status I patients in the control group. OKT3 was given to only two patients receiving amiodarone and 12 control patients at high risk for renal dysfunction. RESULTS Postoperatively, the duration of assisted ventilation was 21 +/- 19 h after amiodarone therapy versus 26 +/- 2 h in the control group (20 +/- 18 h vs. 15 +/- 9 h after excluding patients receiving OKT3), discharge arterial oxygen saturation was > 95% in both groups. Two patients in the amiodarone group with a smoking history of > 100 pack-years developed bilateral pulmonary infiltrates of brief duration. Although patients receiving amiodarone required atrial pacing more frequently (eight vs. two patients) and had a lower heart rate at discharge (75 +/- 18 vs. 86 +/- 11 beats/min), the duration of inotropic support (2.1 +/- 1.5 vs. 3.5 +/- 2.5 days) and of hospital stay (10 +/- 3 vs. 15 +/- 10 days) was not higher in the amiodarone than in the control group. The mortality rate at 30 days was similar in the two groups (6.8% vs. 3.4%, p = NS). CONCLUSIONS Amiodarone therapy before heart transplantation may contribute to occasional pulmonary complications but does not significantly increase perioperative morbidity or mortality with the regimens used in this retrospective study.

UI MeSH Term Description Entries
D007902 Length of Stay The period of confinement of a patient to a hospital or other health facility. Hospital Stay,Hospital Stays,Stay Length,Stay Lengths,Stay, Hospital,Stays, Hospital
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010351 Patient Discharge The administrative process of discharging the patient, alive or dead, from hospitals or other health facilities. Discharge Planning,Discharge Plannings,Discharge, Patient,Discharges, Patient,Patient Discharges,Planning, Discharge,Plannings, Discharge
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D012121 Respiration, Artificial Any method of artificial breathing that employs mechanical or non-mechanical means to force the air into and out of the lungs. Artificial respiration or ventilation is used in individuals who have stopped breathing or have RESPIRATORY INSUFFICIENCY to increase their intake of oxygen (O2) and excretion of carbon dioxide (CO2). Ventilation, Mechanical,Mechanical Ventilation,Artificial Respiration,Artificial Respirations,Mechanical Ventilations,Respirations, Artificial,Ventilations, Mechanical
D002304 Cardiac Pacing, Artificial Regulation of the rate of contraction of the heart muscles by an artificial pacemaker. Pacing, Cardiac, Artificial,Artificial Cardiac Pacing,Artificial Cardiac Pacings,Cardiac Pacings, Artificial,Pacing, Artificial Cardiac,Pacings, Artificial Cardiac
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy.
June 1997, Heart (British Cardiac Society),
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy.
June 2012, World journal of hepatology,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Does amiodarone influence early mortality in heart transplantation?
October 2006, Transplantation proceedings,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Resident education in congenital heart surgery does not compromise outcomes.
January 2022, The Journal of thoracic and cardiovascular surgery,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Does Chiari osteotomy compromise subsequent total hip arthroplasty?
September 2002, The Journal of arthroplasty,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
To use or not to use? Amiodarone before heart transplantation.
May 2017, Surgery,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Cardiomyoplasty does not preclude heart transplantation.
May 1992, The Annals of thoracic surgery,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Prior Femoroacetabular Osteoplasty Does Not Compromise the Clinical Outcome of Subsequent Total Hip Arthroplasty.
April 2021, The Journal of arthroplasty,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Warfarin therapy does not increase bleeding in patients undergoing heart transplantation.
September 2001, The Annals of thoracic surgery,
C Chelimsky-Fallick, and H R Middlekauff, and W G Stevenson, and J Kobashigawa, and L A Saxon, and J Moriguchi, and E D Brownfield, and M A Hamilton, and D Drinkwater, and H Laks
Amiodarone therapy before heart transplantation as a predictor of thyroid dysfunction after transplantation.
August 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Copied contents to your clipboard!